Calamos Wealth Management LLC Buys 57,436 Shares of Danaher Co. (NYSE:DHR)

Calamos Wealth Management LLC raised its stake in shares of Danaher Co. (NYSE:DHR) by 1,646.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 60,925 shares of the conglomerate’s stock after buying an additional 57,436 shares during the period. Danaher comprises approximately 0.7% of Calamos Wealth Management LLC’s investment portfolio, making the stock its 29th biggest holding. Calamos Wealth Management LLC’s holdings in Danaher were worth $13,985,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB bought a new stake in Danaher in the third quarter worth about $5,923,000. Czech National Bank grew its stake in shares of Danaher by 4.2% during the 3rd quarter. Czech National Bank now owns 130,939 shares of the conglomerate’s stock worth $36,404,000 after acquiring an additional 5,320 shares during the period. GAMMA Investing LLC increased its holdings in Danaher by 33.5% in the 3rd quarter. GAMMA Investing LLC now owns 4,480 shares of the conglomerate’s stock worth $1,246,000 after acquiring an additional 1,125 shares during the last quarter. WealthBridge Capital Management LLC lifted its holdings in Danaher by 51.8% during the third quarter. WealthBridge Capital Management LLC now owns 1,465 shares of the conglomerate’s stock valued at $407,000 after purchasing an additional 500 shares during the last quarter. Finally, Diversified Trust Co boosted its position in Danaher by 29.6% during the third quarter. Diversified Trust Co now owns 5,649 shares of the conglomerate’s stock worth $1,571,000 after purchasing an additional 1,289 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $214.09 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The company has a market capitalization of $154.64 billion, a P/E ratio of 40.55, a P/E/G ratio of 2.80 and a beta of 0.83. The business’s 50-day moving average is $235.40 and its two-hundred day moving average is $253.09. Danaher Co. has a fifty-two week low of $214.03 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm posted $2.09 earnings per share. Research analysts predict that Danaher Co. will post 7.77 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is 20.45%.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on DHR shares. Wells Fargo & Company decreased their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Scotiabank began coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target for the company. Stephens restated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Finally, Barclays reduced their target price on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.